Wave faces key test in bid to challenge Sarepta in DMD

Wave faces key test in bid to challenge Sarepta in DMD

Submitted by admin on November 30, 2019 - 11:18pm
Source: 
Biopharma Dive
News Tags: 
Wave Life Sciences
Sarepta Therapeutics
Exondys 51
Duchenne Muscular Dystrophy
Headline: 
Wave faces key test in bid to challenge Sarepta in DMD
snippet: 

Forthcoming trial results will show whether Wave's experimental drug can compete with Sarepta's Exondys 51 in Duchenne muscular dystrophy.

Do Not Allow Advertisers to Use My Personal information